Novel compounds as receptor modulators with therapeutic utility

A method of treating a disorder associated with sphingosine-1-phosphate (S1P) receptor modulation, which comprises administering to a mammal in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula I

• wherein:
• R1 is N or C—R10;
• R2 is aromatic heterocycle, non-aromatic heterocycle, cycloalkyl, cycloalkenyl or aryl;
• R3 is O, N—R11, CH—R12 or S, —CR13═CR14—, —C(O) or —C≡C—;
• R4 is H, aromatic heterocycle, non-aromatic heterocycle, cycloalkyl, cycloalkenyl or aryl;
• R5 is H, halogen, hydroxyl, —OC1-3 alkyl, hydroxyl or C1-3 alkyl;
• R6 is H, C1-3 alkyl, halogen, hydroxyl or —OC1-3 alkyl;
• R7 is H or C1-6 alkyl;
• R8 is H or C1-6 alkyl;
• R9 is —OPO3H2, —COOH, —P(O)(OH)2, —O3-6 alkyl, —S(O)2OH, —P(O)MeOH, —P(O)(H)OH or —OR15;
• R10 is H, C1-6 alkyl, halogen, hydroxyl or —OC1-3 alkyl;
• R11 is H or C1-3 alkyl;
• R12 is H, C1-3 alkyl, halogen, hydroxyl, —OC1-3alkyl or amino;
• R13 is H or C1-3 alkyl;
• R14 is H or C1-3 alkyl;
• R15 is H or C1-3 alkyl;
• L is CHR16, O, S, NR17 or —C(O)—;
• a is 0, 1, 2, 3, 4 or 5;
• b is 0, 1, 2, 3, 4 or 5;
• c is 0 or 1;
• d is 0, 1, 2 or 3;
• R16 is H, C1-3 alkyl, —OC1-3 alkyl, halogen, hydroxyl or amino, and
• R17 is H or C1-3 alkyl;
• with the proviso:
• when R3 is O, N—R12, or S, and b is 0 or 1 then L is not O, S, or NR17;
• and
• when R9 is —OPO3H2, —COOH, —P(O)(OH)2, —S(O)2OH, —P(O)MeOH or —P(O)(H)OH then d is not 0;
• and
• when R9 is OR15 then d is not 0 or 1.